Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the safety, tolerability, efficacy and
pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to
curative surgery or loco regional therapy